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Abstract 
We report a 66-year-old woman with slowly progressive ataxia due to cerebellar atrophy. 
Imaging studies revealed multiple lesions in both the lungs and dorsal subpleural space. 
A biopsy identified the lesions as metastases of a low-grade endometrial stromal 
sarcoma containing sex-cord elements. The histological appearance was identical to a 
uterine tumor the patient was treated for with hysterectomy 16 years before. The 
metastases were removed surgically, and after 3 months ataxia had regressed. We 
conclude that the presenting cerebellar degeneration in this patient resulted from the 
metastatic recurrence of the endometrial tumor. 
 
Introduction 
Paraneoplastic syndromes (PS) represent a heterogeneous group of disorders that 
reflect the remote effects of cancer arising in any specific organ system. Some PS affect the 
nervous system and may precede the detection of the actual cancer by months or even 
years [1]; they can also be indicative for the specific site of the primary cancer. Subacute 
cerebellar degeneration of paraneoplastic origin occurs in approximately two thirds of 
female patients aged ≥50 years [2]. Paraneoplastic cerebellar atrophy (PCA) is a rare 
syndrome that is mainly observed in patients with gynecologic cancers and is 
characterized by widespread loss of Purkinje cells [3]. Clinically, patients may present  
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with predominant or isolated gait ataxia and evidence of truncal and hemispheric 
cerebellar dysfunctions such as diplopia, vertigo, lack of coordination, dysarthria and 
nystagmus [1]. PCA can precede or follow the diagnosis of cancer and has been described 
in patients with malignancies of the breast, ovary, endometrium or fallopian tube [1, 3]. 
Purkinje cell degeneration is associated with circulating anti-Purkinje cell antibodies 
(anti-Yo). Interestingly, in gynecologic cancer patients with cerebellar degeneration, 
tumor cells express the corresponding Purkinje cell antigens [3]. Here, we report a case of 
a patient in whom cerebellar ataxia led to the diagnosis of a multifocal recurrent low-
grade endometrial stromal sarcoma (ESS) with sex-cord elements following a disease-free 
period of 16 years. We describe biological and clinical characteristics of ESS and discuss 
current treatment options. 
Case Report 
A 66-year-old patient was referred to our neurology department with a 3-year history of slowly 
progressing gait ataxia, truncal imbalance, blurred vision due to saccadic eye movements, horizontal 
and vertical gaze-evoked nystagmus (fig. 1a, b), and slight dysarthria. Neurological examination 
disclosed no additional abnormalities. Sixteen years prior to this admission, the patient underwent an 
abdominal hysterectomy with bilateral salpingo-oophorectomy (BSO) for a symptomatic fibroid uterus. 
Unexpectedly, histology revealed a low-grade ESS with sex-cord elements. There was no residual 
disease, and the patient received no adjuvant therapy. Postoperative follow-up and annual screening 
exams were uneventful, and the patient took estrogen-based hormone replacement therapy (HRT). 
On admission, an MRI scan of the brain showed a cerebellar atrophy mainly involving the upper 
vermis (fig. 2a, b). On CT scans of the chest and abdomen, bilateral pulmonary and subpleural 
metastases infiltrating the eighth and ninth thoracic vertebrae were observed (fig. 2c, d). There was no 
evidence of a local recurrence. The cerebrospinal fluid contained 2 leukocytes/μl, was negative for 
malignant cells and oligoclonal bands, and showed a normal protein content and a normal IgG index of 
0.4. Investigations on vitamin E, neurotropic viruses and bacterial agents were negative. In order to 
determine the tumor entity leading to the pulmonary and bone metastases, a CT-guided biopsy of the 
pulmonary lesions was performed, showing that the lesions were metastases of the formerly diagnosed 
low-grade ESS, again containing sex-cord elements (fig. 3). Cells were expressing CD10, had a low 
mitotic rate with 6 mitoses/10 HPF, and 80% were expressing estrogen receptor and 10% progesterone 
receptor. Screening for the antineuronal antibodies anti-Hu, anti-Ri, anti-Yo, anti-CV2, anti-Antiphysin 
and anti-Ma2 in the patient’s serum by IgG immunoblotting showed no significant result. Nevertheless, 
due to the patient’s cerebellar dysfunction combined with the cerebellar atrophy, we performed an 
additional immunohistochemical staining which also disclosed no affinity of the patient’s serum to 
paraffin sections of human cerebellum, excluding the presence of anti-Hu and anti-Yo cerebellar 
antibodies. 
Owing to the clinically suspected paraneoplastic origin of the cerebellar atrophy, the slight 
progression of the metastases within 4 months as evident on a follow-up CT scan of the lungs, and the 
unlikely response to chemotherapy due to a low proliferation index, the decision of the interdisciplinary 
tumor board was to perform surgical debulking in order to remove all evident sites of tumor recurrence. 
In a first operation, a left inferior lobectomy and a mediastinal node dissection were performed, 
removing 3 metastases up to 6 cm in diameter and 44 negative lymph nodes. Synchronously, a 
subpleural metastasis infiltrating the eighth and ninth thoracic vertebrae was removed, with residual 
macroscopic disease requiring postoperative focal radiation therapy. Four weeks later, after an 
uneventful postoperative course, 3 wedge resections of the right superior, middle and inferior lobe as 
well as a lymph node dissection were performed, removing 7 metastases up to 3 cm in diameter and 5 
negative lymph nodes. The patient was discharged at day 10. In the first follow-up visit after the 
radiotherapy, she complained of shortness of breath in consequence of the reduced total lung volume. 
She was counselled to quit her HRT and was prescribed anastrozole as adjuvant therapy with the 
intention to delay further recurrence. After 3 months of follow-up, she is now without evidence of 
tumor. On repeated neurological examination, there was a virtually complete resolution of ataxia, but 
the oculomotor abnormalities persisted (fig. 1c).  
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Discussion 
Our patient presented with clinical signs of slowly progressing ataxia which prompted 
us to a broad search, including for a neoplastic cause. In fact, we found prominent 
thoracic metastases of an ESS which had been treated with hysterectomy 16 years earlier. 
In accordance with a PS [4], the patient’s symptoms regressed after tumor extirpation. 
ESS together with benign endometrial stromal nodules represent a subgroup of 
endometrial stromal tumors derived from uterine mesenchymal tissue (WHO 
classification 2003) and are composed of cells resembling the endometrial stroma in its 
proliferative phase. They are rare, accounting for only 6–20% of all uterine sarcomas and 
0.2% of all uterine malignancies. ESS were formerly divided into high- and low-grade ESS. 
Tumors previously termed high-grade ESS are now called poorly differentiated or 
undifferentiated uterine sarcomas, whereas low-grade tumors are still labelled ESS 
according to the current definition [5]. ESS show infiltrating borders and have a potential 
for recurrence and metastasis [6]. Recently, the International Federation of Gynecology 
and Obstetrics (FIGO) introduced a new classification and staging system in which 
leiomyosarcomas and ESS, due to their similar biology, are classified in 1 staging group 
(FIGO 2009). Both ESS and ESN may contain so-called sex-cord elements, first reported 
by Clement and Scully [7], and have been divided into 2 groups: ESS with sex cord-like 
elements (ESTSCLE) and uterine tumors resembling ovarian sex-cord tumors 
(UTROSCT) [8]. For UTROSCT, sex-cord differentiation is dominant or complete 
(>50%). ESTSCLE contain focal sex cord-like areas in a background of an otherwise 
typical endometrial stromal nodule or ESS. They show an earlier tumor spread, have 
higher recurrence rates and a worse prognosis compared to UTROSCT [8]. Both can be 
considered as polyphenotypic neoplasias most likely derived from pluripotent 
mesenchymal progenitor cells. Accordingly, the tumor of the patient in this report can be 
classified as ESTSCLE. 
Patients with ESS are mostly diagnosed between the age of 40 and 60 years. They may 
present with vaginal bleeding, abdominal pain, or an enlarged uterus which can be 
misinterpreted as a fibroid uterus. Both ultrasonography and MRI are sensitive but not 
specific to detect lesions. Since the endometrium is also involved in most cases, curettage 
can lead to the correct diagnosis. However, as in our patient, diagnosis is mostly 
incidentally made after hysterectomy. 
ESS show an indolent growth and recur even at early stages in 36–56% of cases [6, 9]. 
Recurrences have been reported from 3 months to 23 years after the initial diagnosis, but 
the median time to recurrence ranges between 65 (stage 1) and 9 months (stages 3 and 4), 
respectively, so that long-term follow-up is mandatory. ESS show a considerably benign 
biology as indicated by 5-year survival rates of 62–93%, depending on stage and 
differentiation [10]. Sites of recurrence are mainly the pelvis or other intraperitoneal 
locations, but distant metastases, as in our case, are frequently located in the lungs [6]. 
Therapy 
Due to the rarity of these tumors, information is only available from case reports; 
general treatment recommendations or guidelines based on prospective studies do not 
exist. Recently, Amant et al. [5] have given a comprehensive overview of current 
treatment options. A preoperative noninvasive staging using CT or MR imaging can  
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detect metastatic spread and is mandatory for correct staging. Total hysterectomy in 
combination with BSO and careful abdominal exploration is commonly accepted as 
treatment of choice for early-stage cases confined to the uterus (stage I–II) [5]. Since most 
ESS express hormone receptors, BSO appears to be a logical treatment for a hormone-
sensitive tumor. However, its actual benefit has not been demonstrated, as some studies 
[11] could not find a survival difference in women with ESS treated with or without BSO, 
so that especially in young women with small tumors some authors recommend an 
individualized approach [5]. Although lymph node involvement can already be found at 
early stages in approximately 6–9% of patients, a routine systematic pelvic and periaortic 
lymph node dissection does not appear to provide a survival benefit; thus, only suspicious 
or enlarged nodes should be removed under the aspect of cytoreduction [11, 12]. 
Retrospectively, the patient presented in our report underwent standard initial surgery 
including total hysterectomy and BSO. Considering the generally benign course of the 
disease, in cases of recurrence repeated surgeries aiming to remove all manifestations are 
also a viable treatment option. 
As ESS expresses both estrogen and progesterone receptors, some authors suggested 
that adjuvant-targeted hormonal treatment with either progestins [e.g. 
medroxyprogesterone (250 mg/d) or megestrol (160 mg/d)] or aromatase inhibitors can 
reduce recurrence rates [12, 13]. Sequential administration of progestins (megestrol 
acetate) followed by an aromatase inhibitor (letrozole or anastrozole) has also been 
reported to stabilize or improve the course of the disease. However, there exist no 
prospective studies investigating adjuvant hormonal treatment for ESS; additionally, there 
is no consensus regarding the treatment duration or the potentially additional effect of 
BSO [14].  
Our patient did not receive any adjuvant therapy after the initial surgery. In fact, she 
continued her HRT. Chu et al. [13] speculate in their small case series that estrogen 
replacement after the diagnosis of ESS might be associated with a poor outcome. 
Chemotherapy should be reserved for hormone receptor-negative cases, cases with 
progression or recurrence under progestin or aromatase inhibitor therapy, or those cases 
progressing into a high-grade malignancy. Different regimens have been reported to be 
effective. Combined adjuvant chemotherapy with cisplatin and adriamycin has been 
shown to improve the survival rate in high-risk patients. In a previous GOG study, also 
ifosfamide (1.5 g/m
2 on days 1–5 every 3 weeks) was effective in the therapy of women 
with chemotherapy-naïve, metastatic or recurrent ESS, with an overall response rate of 
33.3%. Additionally, combinatory chemotherapies containing ifosfamide 2 g/m
2, 
epirubicin 40 mg/m
2 and cisplatin 60 mg/m
2, or doxorubicin 50 mg/m
2 and ifosfamide  
5 g/m
2/24 h every 3 weeks were shown to lead to a clinical response in metastatic disease.  
Conclusion 
PS of the nervous system may accompany malignant tumors and require early 
identification and effective treatment of the underlying neoplasm [15]. Cerebellar 
degeneration and its concomitant symptoms have been associated with various 
gynecologic malignancies and therefore require increased awareness of both neurologists 
and gynecologists. We showed that PCA can also occur in combination with late 
recurrent ESS.   
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Fig. 1. Oculomotor abnormalities as evident from electronystagmography. a Gaze-evoked nystagmus 
in fast right and left horizontal saccades. b Abolition of pursuit eye movement by saccades. c Normal 
optokinetic nystagmus in both horizontal directions. 
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Fig. 2. MRI scan of the brain. Slight atrophy of the upper cerebellar vermis and the superior semilunar 
lobes in a sagittal (a) and axial projection (b). Chest X-ray (c) and CT scan (d): several bilateral 
pulmonary metastases and a subpleural metastasis posterior of the left ventricle (arrow). 
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Fig. 3. HE morphology and immunohistochemistry of a lung metastasis of the low-grade ESS.  
a Morphological assessment revealed a tumor composed of round to oval cells with slightly 
pleomorphic nuclei and small nucleoli as well as hyaline intercellular substance between the tumor 
cells in the HE stain (×200 magnification). b Immunohistochemical analysis revealed CD10 positivity 
of the tumor cells (×200 magnification). 
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